To ask the Secretary of State for Health and Social Care, what assessment has been made of the potential merits of making mercaptamine hydrochloride eye drops available through the NHS.
This answer is the replacement for a previous holding answer.
22 April 2021
Current clinical commissioning policy is that mercaptamine hydrochloride eye drops are not recommended to be available as a treatment option through routine commissioning for corneal cystine deposits, following the prioritisation process undertaken by NHS England and NHS Improvement in July 2020. However, NHS England and NHS Improvement have determined that there is sufficient clinical evidence to consider commissioning mercaptamine hydrochloride eye drops. This treatment will therefore be considered at the Clinical Priorities Advisory Group prioritisation meeting in May 2021, along with a number of other treatments being considered for funding.